EPA:SIGHT • FR0013183985
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GENSIGHT BIOLOGICS SA (SIGHT.PA).
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.582M -51.06% | 1.267M -50.93% | 1.5M 18.39% | 3.605M 140.33% | 3.09M -14.29% | 30.9M 900.00% | N/A | N/A | N/A | |
| EBITDA YoY % growth | -26.774M 1.56% | -27.517M -2.78% | -14.754M 46.38% | -27.295M -85.00% | -30.9M -13.21% | -19.055M 38.33% | N/A | N/A | N/A | |
| EBIT YoY % growth | -27.835M 1.03% | -29.696M -6.69% | -15.813M 46.75% | -23.175M -46.56% | -25.75M -11.11% | -19.57M 24.00% | 143.98M 835.72% | 210.23M 46.01% | 275.99M 31.28% | |
| Operating Margin | -1,078.04% | -2,343.80% | -1,054.20% | -642.86% | -833.33% | -63.33% | N/A | N/A | N/A | |
| EPS YoY % growth | N/A -52.00% | N/A 28.07% | N/A 11.28% | -0.50 | -0.90 -80.41% | -1.00 -10.86% | N/A | N/A | N/A |
All data in EUR
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
11 analysts have analysed SIGHT.PA and the average price target is 0.44 EUR. This implies a price increase of 416% is expected in the next year compared to the current price of 0.085.
GENSIGHT BIOLOGICS SA (SIGHT.PA) will report earnings on 2026-03-26, after the market close.
The number of analysts covering GENSIGHT BIOLOGICS SA (SIGHT.PA) is 11.